Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.
Related Articles
Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.
All-Oral Combo Yields High Response Rate in Relapsed/Refractory AML – Oncology Nurse Advisor
Revumenib, venetoclax, and ASTX727 (a fixed-dose combination of decitabine and cedazuridine) demonstrated efficacy in patients with relapsed or refractory AML.
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy…
Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
From Patient to Advocate in the Fight Against Childhood… : Oncology Times
An abstract is unavailable.
BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
